JLE

Médecine

MENU

Platelet aggregation inhibitors in primary prevention in the elderly. State of play of professional practices Volume 19, issue 1, January 2023

Figures


  • Figure 1.

Tables

Authors
Faculté de médecine de Limoges, 2 rue du Docteur Marcland, 87025 Limoges
Correspondance : K. Rudelle
karen.rudelle@unilim.fr

Introduction

Antiplatelet agents are the 2nd most prescribed therapeutic class in the elderly. Since 2012, many studies have warned of their increased risk of bleeding in the primary prevention of cardiovascular events. In 2016, the European Society of Cardiology recommends an individual assessment of the benefit/risk balance. Currently, there is a lack of consensus on antiplatelet agents in primary prevention.

Purpose of research

The objective of this study was to assess the prevalence of renewal of antiplatelet agents in the over 75s in primary prevention in general practice. The evaluation of professional practices was carried out with 24 general practitioners from New Aquitaine.

Results

One hundred and thirteen questionnaires were analyzed. One hundred and five patients (93 %) saw their treatment renewed. Ten percent had no cardiovascular risk factor. Forty-two percent had a cardiovascular risk factor. Thirty-one percent had two cardiovascular risk factors. Twenty-nine patients (25.7 %) had a bleeding history or risk factor. The reasons for renewal were good treatment tolerance (50.5 %), renewal by the specialist (41.9 %), cardiovascular risk considered high (37.1 %), lack of time (13.3 %) and refusal to stop the patient (4.8 %). The treatment was stopped in the event of repeated falls (50 %) or serious bleeding (37.5 %).

Conclusions

This evaluation of professional practices showed frequent use of antiplatelet agents in the over 75s for primary prevention and primary care.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License